United Therapeutics (NASDAQ:UTHR) CEO Sells $1,898,320.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $474.58, for a total transaction of $1,898,320.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $61,695.40. This trade represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $474.82 on Friday. The company has a market capitalization of $20.44 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $485.32. The company has a 50-day simple moving average of $439.78 and a 200 day simple moving average of $355.90.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the company earned $6.39 earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Clearstead Advisors LLC increased its position in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 23 shares during the period. Bessemer Group Inc. boosted its position in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 28 shares during the period. Archer Investment Corp grew its stake in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 31 shares in the last quarter. F m Investments LLC grew its stake in United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 33 shares in the last quarter. Finally, HB Wealth Management LLC increased its holdings in United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 35 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on UTHR. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. UBS Group increased their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.